Lifevantage Corp
LFVN evidence brief
What we can confirm
- BioSniper Score:
- 5.9 / 10
- Market Cap:
- $79.5M
What it means
What to watch
Prepared research question
What matters most for LFVN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · LFVN
LifeVantage Corp (LFVN) is a science-based nutraceutical company focused on cellular health products, including its proprietary P84 formula and the new MindBody GLP-1 System, currently navigating a leadership transition and challenging operating environment.
Key risk: Operating environment challenges
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$79.5M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
LifeVantage Corp (LFVN) is a science-based nutraceutical company focused on cellular health products, including its proprietary P84 formula and the new MindBody GLP-1 System, currently navigating a leadership transition and challenging operating environment.
- LifeVantage is a science-based company that develops nutraceutical products to help people reach their health and wellness goals [sec · filed 2025-09-19].
- The company reported shareholders' equity of $33.6M as of 2026-06-30 [sec].
- Fiscal year 2026 marked a period of transition including leadership succession and continued investment in digital capabilities and eCommerce platform enhancements [sec · filed 2026-09-18].
- New in vitro research shows P84 positively influences gut peptide production, with one peptide increased by more than 1,000% [news · published 2025-11-12].
- The company is focused on long-term growth strategies including the launch of its patent-pending MindBody GLP-1 System designed to support weight management and wellness [sec · filed 2025-09-19].
What works
- The company has a science-based foundation and is developing novel products like the patent-pending MindBody GLP-1 System, which may address the large weight management market [sec · filed 2025-09-19].
- New in vitro study results for its proprietary P84 formula show strong biological activity in gut peptide production, with one peptide increased by more than 1,000%, supporting its cellular health platform [news · published 2025-11-12].
- The company maintains a balanced capital allocation strategy including returning stockholder value through quarterly dividends and opportunistic share repurchases [sec_mda · as of 2026-08-27].
What to weigh
- Fiscal year 2026 was described as a challenging operating environment, with the company facing headwinds that required foundational work rather than growth [sec · filed 2026-09-18].
- Working capital decreased from $23.7M at June 30, 2025 to $18.1M at June 30, 2026, primarily due to decreases in cash, inventory, and prepaid expenses [sec_mda · as of 2026-08-27].
- The company is in a transition period with leadership succession and ongoing enhancement of governance, which can create execution risk [sec · filed 2026-09-18].
From the filings
Quoted directly from source documents.
Fiscal year 2026 was a period of transition and challenging operating environment
“Fiscal year 2026 marked an important period of transition for LifeVantage Corporation, including leadership succession, continued investment in strategic initiatives, and ongoing enhancement of the Company's governance and Board capabilities. While the Company faced a challenging operating environment during fiscal year 2026”
SEC filings · September 18, 2026
P84 positively impacts gut peptide production in vitro
“New in vitro research shows P84 influences key gut peptides – including one by more than 1,000% – supporting cellular pathways tied to regulation, repair, and restoration”
News · November 12, 2025
Working capital decreased from prior year
“At June 30, 2026, we had working capital (current assets minus current liabilities) of $18.1 million compared to working capital of $23.7 million at June 30, 2025.”
SEC MD&A · August 27, 2026
Company is focused on long-term growth strategies including MindBody GLP-1 System
“Overall, we are focused on long-term growth strategies for our business, including the launch of our new patent-pending MindBody GLP-1 System ™ designed to support weight management and wellness by activating GLP-1”
SEC filings · September 19, 2025
Catalyst timeline
- 2024-01-30 · Earnings Report - SEC 8-K filing — Routine quarterly earnings report providing financial performance update.
- 2024-05-02 · Earnings Report - SEC 8-K filing — Routine quarterly earnings report providing financial performance update.
- 2024-08-28 · Earnings Report - SEC 8-K filing — Routine quarterly earnings report providing financial performance update.
- 2024-10-29 · Earnings Report - SEC 8-K filing — Routine quarterly earnings report providing financial performance update.
- 2025-02-05 · Earnings Report - SEC 8-K filing — Routine quarterly earnings report providing financial performance update.
- 2025-05-06 · Earnings Report - SEC 8-K filing — Routine quarterly earnings report providing financial performance update.
- 2025-09-04 · Earnings Report - SEC 8-K filing — Routine quarterly earnings report providing financial performance update.
- 2025-11-04 · Earnings Report - SEC 8-K filing — Routine quarterly earnings report providing financial performance update.
Risks & what to watch (3)›
Key risks
- Operating environment challenges — Fiscal year 2026 faced a challenging operating environment, with the company completing foundational work rather than achieving growth [sec · filed 2026-09-18].
- Working capital decline — Working capital decreased from $23.7M to $18.1M year-over-year, driven by lower cash and inventory [sec_mda · as of 2026-08-27].
- Leadership transition risk — The company is undergoing leadership succession, which can create uncertainty in strategy and execution [sec · filed 2026-09-18].
What to watch
- Monitor upcoming earnings reports for fiscal year 2027 to assess whether the challenging operating environment is improving [sec · filed 2026-09-18].
- Track commercial progress of the MindBody GLP-1 System launch, as it represents a key growth strategy [sec · filed 2025-09-19].
- Watch for further clinical or in vitro data on P84 and its potential to drive product differentiation [news · published 2025-11-12].
- Observe changes in working capital and cash position in future filings to gauge financial health [sec_mda · as of 2026-08-27].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated September 27, 2026 · How we verify sources →
Run Lifevantage Corp through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Lifevantage Corp facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.85
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 1 sell (180d)
Financials
Short Interest
as of May 13, 2026- % of float
- 38.6%
- Days to cover
- 21.6
- Shares short
- 3,853,011
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
LFVN short interestGovernance
Frequently asked questions
What is the AI investment thesis for Lifevantage Corp?
LifeVantage Corp (LFVN) is a science-based nutraceutical company focused on cellular health products, including its proprietary P84 formula and the new MindBody GLP-1 System, currently navigating a leadership transition and challenging operating environment.
Who is the CEO of Lifevantage Corp?
Mr. Terrence O. Moorehead is the chief executive officer of Lifevantage Corp (LFVN).
Where is Lifevantage Corp headquartered?
Lifevantage Corp (LFVN) is headquartered in Lehi, UT, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.